Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.66 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6240191 | 0.84 | UBE2T (0.61) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2791997 | 0.83 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL31275849 | 0.83 | UBE2T (0.66) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL226465 | 0.83 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19372016 | 0.83 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL23970354 | 0.82 | UBE2T (0.59) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3005360 | 0.82 | UBE2T (0.63) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| Bromide SCHEMBL7601035 | 0.81 | UBE2T (0.68) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL5154626 | 0.80 | UBE2T (0.61) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL29406561 | 0.80 | UBE2T (0.61) | UBE2TASIC3SMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970328-B1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-04-26 | — | — | EP | claimed |
| CN-105358561-A | Novel inhibitor compounds of phosphodiesterase type 10a | ABBVIE DEUTSCHLAND | 2016-02-24 | — | — | CN | claimed |
| EP-2970328-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-20 | — | — | EP | claimed |
| US-9200005-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-12-01 | — | — | US | claimed |
| US-9139567-B2 | Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-22 | — | — | US | claimed |
| WO-2014140086-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | WO | claimed |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | claimed |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-07 | — | — | US | claimed |
| EP-2734516-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Boehringer Ingelheim International GmbH (DE) | 2014-05-28 | — | — | EP | claimed |
| WO-2013012844-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | WO | claimed |
| WO-2010138833-A1 | SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2010-12-02 | — | — | WO | claimed |
| US-5750558-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| WO-1997041100-A1 | IMINOXY DERIVATIVES OF INDOLE AND INDENE COMPOUNDS AS INHIBITORS OF PROSTAGLANDIN BIOSYNTHESIS | ABBOTT LABORATORIES (US) | 1997-11-06 | — | — | WO | claimed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| EP-3793602-A1 | TREATMENT OF AGING-ASSOCIATED DISEASE WITH MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Alkahest, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-5202336-A | Lipoxygenase inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 1993-04-13 | — | — | US | disclosed |
| US-5093340-A | Lipoxygenase enzyme inhibitors, antithrombolytic agents | BAYER AKTIENGESELLSCHAFT (DE) | 1992-03-03 | — | — | US | disclosed |
| CN-1057839-A | The azepine benzoglyoxaline that is used for the treatment of asthma, sacroiliitis and relative disease | PFIZER (US) | 1992-01-15 | — | — | CN | disclosed |
| US-5070096-A | ANTICOAGULANTS, LIPOXYGENASE INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | UBE2T 2273/4885ASIC3 3305/4885SMN1; SMN2 1581/4885 |
| US-20140275069-A1 | Novel inhibitor compounds of phosphodiesterase type 10A | PDE5A, PDE3A, PDE3B | UBE2T 2493/4885ASIC3 3208/4885SMN1; SMN2 1019/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | UBE2T 2273/4885ASIC3 3305/4885SMN1; SMN2 1581/4885 |
| US-20140221373-A1 | ARYLPYRAZOLE ETHERS AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | UBE2T 1136/4885ASIC3 1333/4885SMN1; SMN2 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.